|
|
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30
|
|
Download |
|
|
|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
47,380,000 |
Market
Cap: |
N/A |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$ - $ |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Inhibrx is a clinical-stage biotechnology company with a pipeline of novel biologic therapeutic candidates, developed using protein engineering and Co.'s proprietary single domain antibody, or sdAb, platform. Co. has four programs in ongoing Phase 1 clinical trials, three for the treatment of various cancers, and one for Alpha-1 Antitrypsin Deficiency. Co.'s most advanced therapeutic candidate, INBRX-109, is a tetravalent death receptor 5, or DR5, agonist being evaluated in patients diagnosed with chondrosarcoma and mesotheliom. INBRX-106 is a hexavalent OX40 agonist developed for patients with locally advanced or metastatic solid tumors. Co. is also developing INBRX-105 and INNBRX-101.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
511,627 |
1,844,960 |
Total Buy Value |
$0 |
$0 |
$9,899,982 |
$49,899,839 |
Total People Bought |
0 |
0 |
1 |
1 |
Total Buy Transactions |
0 |
0 |
1 |
2 |
Total Shares Sold |
0 |
0 |
0 |
502,060 |
Total Sell Value |
$0 |
$0 |
$0 |
$12,346,854 |
Total People Sold |
0 |
0 |
0 |
3 |
Total Sell Transactions |
0 |
0 |
0 |
22 |
End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Shabet Rose Sharon |
|
|
2023-08-28 |
4 |
B |
$19.35 |
$9,899,982 |
I/I |
511,627 |
511,627 |
0.01 |
- |
|
Eckelman Living Trust Dated February 5, 2014 |
10% Owner |
|
2023-03-01 |
4 |
AS |
$24.20 |
$968,231 |
I/I |
(40,000) |
2,035,553 |
|
- |
|
Lappe Family Trust |
To be Verified |
|
2023-02-28 |
4 |
AS |
$25.02 |
$1,501 |
I/I |
(60) |
2,486,192 |
|
- |
|
Eckelman Living Trust Dated February 5, 2014 |
10% Owner |
|
2023-02-02 |
4 |
AS |
$25.40 |
$286,355 |
I/I |
(11,250) |
2,075,553 |
|
- |
|
Eckelman Living Trust Dated February 5, 2014 |
10% Owner |
|
2023-02-01 |
4 |
AS |
$24.29 |
$710,856 |
I/I |
(28,750) |
2,086,803 |
|
- |
|
Lappe Family Trust |
To be Verified |
|
2023-01-24 |
4 |
AS |
$25.71 |
$111,478 |
I/I |
(4,335) |
2,486,252 |
|
- |
|
Lappe Family Trust |
To be Verified |
|
2023-01-23 |
4 |
AS |
$25.36 |
$549,364 |
I/I |
(21,665) |
2,490,587 |
|
- |
|
Kayyem Jon Faiz |
Director |
|
2023-01-23 |
4 |
AS |
$25.26 |
$239,999 |
I/I |
(9,500) |
3,224,301 |
|
- |
|
Eckelman Living Trust Dated February 5, 2014 |
10% Owner |
|
2023-01-04 |
4 |
AS |
$23.11 |
$166,829 |
I/I |
(7,105) |
2,115,553 |
|
- |
|
Eckelman Living Trust Dated February 5, 2014 |
10% Owner |
|
2023-01-03 |
4 |
AS |
$23.41 |
$781,770 |
I/I |
(32,895) |
2,122,658 |
|
- |
|
Kayyem Jon Faiz |
Director |
|
2022-12-21 |
4 |
AS |
$26.87 |
$256,679 |
I/I |
(9,500) |
3,233,801 |
|
- |
|
Lappe Family Trust |
To be Verified |
|
2022-12-19 |
4 |
AS |
$25.53 |
$664,443 |
I/I |
(26,000) |
2,512,252 |
|
- |
|
Eckelman Living Trust Dated February 5, 2014 |
10% Owner |
|
2022-12-06 |
4 |
AS |
$26.83 |
$1,088,683 |
I/I |
(40,000) |
2,155,553 |
|
- |
|
Kayyem Jon Faiz |
Director |
|
2022-11-21 |
4 |
AS |
$29.33 |
$283,972 |
I/I |
(9,500) |
3,243,301 |
|
- |
|
Lappe Family Trust |
To be Verified |
|
2022-11-17 |
4 |
AS |
$25.36 |
$724,910 |
I/I |
(26,000) |
2,538,252 |
|
- |
|
Eckelman Living Trust Dated February 5, 2014 |
10% Owner |
|
2022-11-01 |
4 |
AS |
$33.34 |
$1,340,387 |
I/I |
(40,000) |
2,195,553 |
|
- |
|
Kayyem Jon Faiz |
Director |
|
2022-10-21 |
4 |
AS |
$29.39 |
$286,232 |
I/I |
(9,500) |
3,252,801 |
|
- |
|
Lappe Family Trust |
To be Verified |
|
2022-10-17 |
4 |
AS |
$28.66 |
$769,443 |
I/I |
(26,000) |
2,564,252 |
|
- |
|
Shabet Rose Sharon |
|
|
2022-10-07 |
4 |
B |
$30.00 |
$39,999,857 |
I/I |
1,333,333 |
333,333 |
0.01 |
- |
|
Eckelman Living Trust Dated February 5, 2014 |
10% Owner |
|
2022-10-04 |
4 |
AS |
$24.67 |
$1,112,813 |
I/I |
(40,000) |
2,235,553 |
|
- |
|
Eckelman Living Trust Dated February 5, 2014 |
10% Owner |
|
2022-09-13 |
4 |
GA |
$0.00 |
$0 |
I/I |
160,000 |
160,000 |
|
- |
|
Eckelman Living Trust Dated February 5, 2014 |
10% Owner |
|
2022-09-13 |
4 |
GD |
$0.00 |
$0 |
I/I |
160,000 |
2,275,553 |
|
- |
|
Eckelman Living Trust Dated February 5, 2014 |
10% Owner |
|
2022-09-06 |
4 |
AS |
$14.86 |
$596,274 |
I/I |
(40,000) |
2,435,553 |
|
- |
|
Kayyem Jon Faiz |
Director |
|
2022-08-24 |
4 |
GD |
$0.00 |
$0 |
I/I |
11,900 |
3,262,301 |
|
- |
|
Kayyem Jon Faiz |
Director |
|
2022-08-05 |
4 |
GD |
$0.00 |
$0 |
I/I |
3,400 |
3,274,201 |
|
- |
|
51 Records found
|
|
Page 1 of 3 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|